28 September 2023FeaturesBig PharmaVincent Shier

Why Fed Circ's 'Cellect' decision cannot be ignored

US patent holders may want to rethink their patent portfolio strategies following the recent decision by the Court of Appeal for the Federal Circuit in In re Cellect.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Fed Circ weighs in on pipette mechanism claim construction

2 November 2023 Precedential ruling finds errors in lower court’s findings in a case concerning medical devices | Earlier verdict has been vacated and remanded.

Americas

'Cellect': why patent term adjustment is ripe for review

5 October 2023 In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.

Big Pharma

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.